AX1 impresses in Copenhagen: Occuity at ESCRS and Ophthalmology Futures

This September, Mark Jenkins (our CCO) and I travelled to Copenhagen for what has become one of the highlights of the ophthalmology calendar – the ESCRS Congress. With thousands of eye doctors, industry suppliers, manufacturers, and distributors gathering in one place, ESCRS creates an unparalleled opportunity for connection and collaboration.

Although we don’t exhibit at the Congress itself, we take full advantage of having the global ophthalmic community together in one city. Each year, we set up a base nearby and run back-to-back meetings from early morning until late evening. It’s intense but always incredibly productive – and this year was no exception.

Occuity CCO, Mark Jenkins was invited to present at Ophthalmology Futures Forum in Copenhagen.

A Prestigious Start: Ophthalmology Futures Forum

Before ESCRS officially began, we were honoured to be selected as one of the ophthalmic industries most exciting start-ups, and given the opportunity to present to present at the Ophthalmology Futures Forum. This select gathering brings together some of the most innovative businesses launching into the market, alongside an illustrious audience of leading doctors and specialists in glaucoma, refractive surgery, and myopia.

Our CCO, Mark Jenkins, delivered the presentation at the historic Hotel d’Angleterre. The response was fantastic. Not only did we receive strong interest in our current funding round, but the presentation also led directly to a series of follow-up meetings with potential partners and industry leaders.

Back-to-Back Meetings

From there, our schedule didn’t slow down. Over the following days, we held back-to-back meetings with distribution partners covering Australia, France, Germany, Belgium, the Nordics, South America and beyond. These sessions gave us valuable insights into their local markets, allowed us to discuss our pipeline of products, and provided the opportunity to demonstrate our pre-production AX1 prototypes.

We were encouraged by the feedback on the PM1 Pachymeter from our distribution partners. The launch of any new medical device into multiple markets takes time, but the PM1 is now being sold in more than 20 countries. Alongside sales, the device is also being provided to KOLs (key opinion leaders) in those markets to help raise awareness and build clinical advocacy.

The market for the PM1 is relatively mature and represents more of a replacement opportunity. With an estimated 70,000 handheld ultrasound pachymeters in use globally, many of which will require replacement in the coming years, the PM1’s advantages are clear. Its non-contact design and lack of consumables offer significant benefits over existing contact ultrasound devices.

One particularly valuable discussion focused on the PM1’s application in corneal cross-linking, a procedure used to treat keratoconus. Because ultrasound devices carry a risk of damage and infection, they are not used in this setting. The PM1’s optical technology avoids these risks, making this an exciting new opportunity that we are now exploring further.

And of course, all eyes were on the AX1 Axiometer™. The response to the AX1 pre-production prototypes was remarkable. Testament to their speed and intuitive user experience, many people were able to pick up the devices and take accurate measurements within seconds – a powerful demonstration of how user-friendly the technology is.

The consensus was clear: myopia management is moving rapidly into the mainstream, and the AX1 is perfectly positioned to meet that demand by giving practitioners a faster, more accessible, and patient-friendly tool.

Alongside our distribution meetings, we also had a number of engaging conversations with major corporates who are keen to learn more about our technology and its potential impact.

The AX1: Poised to Transform Myopia Management

The AX1 is more than just a new device – it represents a step-change in how eye care professionals can approach myopia management. By providing a faster, more accessible, and patient-friendly way to measure axial length, the AX1 enables practitioners not only to deliver better clinical outcomes but also to enhance the overall patient experience.

Equally important, it allows eye doctors to offer a commercially attractive service, expanding their practice capabilities while meeting a pressing duty of care: helping children and families manage the risks of myopia progression.

Within just a few minutes, distributors were able to deliver repeatable axial length measurements with the AX1.

Looking Ahead

Our time in Copenhagen was a huge success. From presenting at Ophthalmology Futures to the many back-to-back meetings during ESCRS, it’s clear Occuity’s handheld, non-contact devices are gaining increased awareness and interest.

The global ophthalmology community is ready for innovation, and we are more confident than ever that the AX1 will play a defining role in reshaping the myopia management market.

Occuity's investment round is now open.

HNW & Sophisticated Investors are invited to find out more by registering on our website.

Interested investors, can also invest now via Crowdcube: Please click here

Visit Crowdcube

Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong. Take 2 mins to learn more.